Teva Pharmaceutical (TEVA) Plunges 1.44% to 2025 Low Amid Layoffs, Strategic Shifts

The share price of Teva Pharmaceutical (TEVA) hit its lowest level since September 2025, with an intraday decline of 1.44%, marking a significant drop amid ongoing strategic challenges.

The company’s recent announcement of 2,400 layoffs—8% of its global workforce—has intensified concerns about its cost-cutting efforts under the “Pivot to Growth” strategy. These reductions, excluding roles in its Japanese generics joint venture, aim to achieve $700 million in annual savings by 2027. The move reflects a broader industry trend of operational streamlining but raises questions about short-term execution risks and employee morale.

Structural imbalances in the U.S. generic drug market further weigh on Teva’s outlook. Generics, which dominate prescription volume, face razor-thin margins and limited incentives compared to branded drugs. Pharmacy benefit managers (PBMs) exacerbate this by favoring high-rebate branded medications, creating barriers for lower-cost alternatives. Teva’s restructuring highlights the urgent need for systemic reforms to rebalance pricing dynamics and ensure equitable access.

Shifting focus to branded pharmaceuticals, Teva has seen growth in products like Austedo and Ajovy, which contributed to a 39% year-over-year sales increase in Q1 2025. However, this pivot requires sustained R&D investment and operational efficiency, with plans to consolidate manufacturing sites to fewer than 30 by 2027. While this strategy aims to boost profitability, it also demands careful navigation of regulatory and market risks.

Divesting its active pharmaceutical ingredient (API) business, now classified as “held for sale,” underscores Teva’s commitment to simplifying operations. This decision aligns with industry trends of shedding non-core assets to prioritize innovation and profitability. The API unit’s commoditized nature and high costs make its disposal a logical step, though execution timelines remain critical for investor confidence.

Global pricing distortions and potential regulatory shifts, including pharmaceutical tariffs, add further uncertainty. Teva’s reduced 2025 sales guidance—from $17.4 billion to $16.8–$17.2 billion—reflects macroeconomic headwinds and generics segment challenges. Investors are now weighing the company’s long-term growth potential against these short-term pressures, contributing to recent volatility.